Target intelligence / Profile preview

Nicotinic acetylcholine receptor (alpha 3 beta 4 subtype) (α3β4 nAChR)

Target
α3β4 nAChR
Molecular classification
Ligand-gated ion channel, Cys-loop receptor, Receptor
01

Overview

The α3β4 nicotinic acetylcholine receptor (nAChR) is a pentameric ligand-gated ion channel primarily found in autonomic ganglia, the adrenal medulla, and specific brain regions like the medial habenula and interpeduncular nucleus. It plays a crucial role in fast synaptic transmission by mediating cation influx upon activation by acetylcholine or other agonists. This receptor subtype is implicated in drug-seeking behavior, nicotine reward, and physical withdrawal symptoms. Genetic variations in the CHRNA5/A3/B4 gene cluster, which encodes the α3 and β4 subunits, are associated with increased risk for nicotine dependence and other diseases. Selective antagonists of the α3β4 nAChR are being investigated as potential anti-addictive therapies.

Other names
α3β4 receptorGanglion-type nicotinic receptor
02

Mechanism of action

Ligand binding opens the ion channel, leading to Na+ and K+ influx and neuronal depolarization.

03

Biological functions

Fast synaptic transmissionNeuronal excitationAutonomic nervous system signalingModulation of drug-reward pathways
04

Disease associations

Nicotine dependenceAddictionLung cancer (genetic association)COPD (genetic association)Seizures
05

Safety considerations

Potential for off-target effects due to sequence similarity with other nAChR subtypes.Development of tolerance and dependence with chronic agonist exposure.
06

Interacting drugs

Acetylcholine

23 more in the full profile.

07

Biomarkers

CHRNA5/A3/B4 gene cluster polymorphisms (risk for nicotine dependence, lung cancer, COPD)

Beyond the preview

Go deeper on Nicotinic acetylcholine receptor (alpha 3 beta 4 subtype) (α3β4 nAChR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nicotinic acetylcholine receptor (alpha 3 beta 4 subtype) (α3β4 nAChR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call